Endocrine Abstracts

Background: Pituitary adenomas (PA) are considered very rare conditions, with an estimated prevalence of 25 cases/100 000 inhabitants. However, community-based studies on the prevalence of PA are currently scant.Aim: To ascertain the prevalence of PA and the characteristics of the patients diagnosed with them in a large population of inhabitants.Methods: A survey on the GP surgeries of Banbury (Oxfordshire, UK) covering 89 334 inha...

Background: Pituitary adenomas (PA) have traditionally been considered as very rare conditions, with an estimated prevalence of 25 cases/100 000 inhabitants. However, these data have been extracted either from cancer registries or from hospital databases and therefore, may not be accurate.Aim: To ascertain the prevalence of PA and the characteristics of the patients diagnosed with them in a large population of inhabitants.Methods: ...

Non-functioning pituitary adenomas (NFA) are associated with significant morbidity. Published data on the quality of life (QoL) of NFA patients are scarce and conflicting: some studies indicate a reduced QoL in patients with adequately treated NFAs while others demonstrate that subjective health-related QoL is not compromised to any major extent compared to the general population. Most published studies indicate specific subgroups of patients which are particularly affected, w...

Generously supported by IPSEN)-->GH replacement (GHR) in adults has demonstrated to improve body composition, inflammatory cardiovascular biomarkers and quality of life. However, this benefit is uneven, and factors that stratify treatment response are required.According to current guidelines, low IGF-I levels in specific conditions provide strong evidence for GH deficiency (GHD). Nevertheless, normal levels do ...

Data on the quality of life (QoL) of patients with non-functioning pituitary adenoma (NFA) are sparse and conflicting. We have therefore evaluated the QoL in patients with NFAs followed-up in a tertiary UK referral centre and explored the impact of various factors. Three validated questionnaires (Short Form 36-SF36, Nottingham Health Profile-NHP and European Quality of Life Scale-EuroQoL) were offered to consecutive NFA subjects attending outpatient clinics over a 6-month peri...

Background: Nadir GH<2 mU/l in OGTT, normal IGF-I and mean GH<5 mU/l in the growth hormone day curve (GHDC) are considered the therapeutic endpoints in patients with acromegaly. However, discrepancies between these parameters have been reported.Aim: To compare the utility of the above tests in assessing the acromegaly status following surgical treatment.Patients and methods: Twenty-six consecutive patients (16 females) diag...

Background: Acromegaly, a chronic disease caused by excess secretion of growth hormone (GH), has been known to reduce patients life expectancy. This increase in morbility and mortality is not only due to cardiovascular, respiratory or cerebrovascular disorders, but also to an increased risk for cancer.Subjects and methods: The aim of this study was to describe the associated malignant diseases among our fifty acromegalic patients. Clinical features of th...